```html

Kernicterus (Neurologic Signs)

What is Kernicterus (neurologic signs)?

Kernicterus is a rare but serious form of brain injury caused by very high levels of unconjugated (Indirect) bilirubin crossing the blood‑brain barrier in newborn infants. When bilirubin accumulates in specific areas of the brain—principally the basal ganglia, subthalamic nuclei, hippocampus, and certain cranial nerve nuclei—it produces characteristic neurologic signs, collectively referred to as kernicterus.

The term “kernicterus” originally described the yellow‑brown discoloration of these brain structures seen on autopsy. In clinical practice, the phrase “kernicterus (neurologic signs)” is used to highlight the functional manifestations that may appear shortly after birth or, in milder cases, develop months later as a chronic neurologic sequela.

Because bilirubin is neurotoxic at high concentrations, prompt recognition and treatment of severe hyperbilirubinemia are critical to prevent irreversible damage.

Common Causes

Any condition that leads to markedly elevated unconjugated bilirubin in a newborn can precipitate kernicterus. The most frequent contributors are:

• Hemolytic disease of the newborn (HDN) – maternal‑fetal blood group incompatibility (e.g., Rh or ABO).
• Neonatal hemolysis due to enzyme deficiencies – such as G6PD deficiency or pyruvate kinase deficiency.
• Prematurity – immature liver enzymes (UDP‑glucuronosyltransferase) limit bilirubin conjugation.
• Breast‑feeding jaundice – inadequate intake in the first days leads to dehydration and reduced bilirubin excretion.
• Breast‑milk jaundice – a later, often more prolonged rise in bilirubin due to substances in breast milk that inhibit bilirubin conjugation.
• Crigler‑Najjar syndrome type I – a rare genetic absence of UDP‑glucuronosyltransferase activity.
• Physiologic jaundice of the newborn – normally peaks at 3‑5 days but can become dangerous when combined with other risk factors.
• Sepsis or severe infection – increases hemolysis and impairs hepatic clearance.
• Inborn errors of metabolism – e.g., galactosemia, where toxic metabolites impair bilirubin conjugation.
• Use of certain drugs – e.g., sulfonamides, some antibiotics, or maternal medication that displaces bilirubin from albumin.

Associated Symptoms

The neurologic signs of kernicterus overlap with other neonatal neurologic disorders, but a classic pattern emerges:

• Acute encephalopathy – lethargy, poor feeding, high‑pitched cry, or seizures.
• Hypotonia – floppy or “floppy‑baby” appearance.
• Movement disorder – choreo‑athetoid movements (involuntary writhing) that become more pronounced as the child ages.
• Auditory dysfunction – sensorineural hearing loss may appear weeks to months later.
• Ocular disturbances – gaze palsy, nystagmus, or “sun‑setting” eyes.
• Dental enamel hypoplasia – a long‑term consequence of early bilirubin toxicity.
• Developmental delay – slowed motor milestones and cognitive impairment.
• Spasticity or cerebral palsy‑like picture – often a chronic sequela when injury is severe.

It is essential to differentiate these signs from other causes of neonatal encephalopathy (e.g., hypoxic‑ischemic injury, infection, metabolic disorders).

When to See a Doctor

Because bilirubin can rise quickly, parents and caregivers should be vigilant. Seek medical attention immediately if the newborn shows any of the following:

• Yellowing of the skin that spreads beyond the face and chest, or appears to darken.
• Lethargy, excessive sleepiness, or inability to wake for feeds.
• High‑pitched, inconsolable crying or sudden change in cry quality.
• Feeding difficulties—poor latch, reduced intake, or vomiting.
• Seizure‑like activity (jerking movements, eye deviation, stiffening).
• Weak or floppy tone, especially in the arms and legs.
• Any sign of dehydration (dry mouth, fewer wet diapers).

Even if the baby seems “okay,” infants with risk factors (prematurity < 38 weeks, known hemolysis, family history of bilirubin disorders) should have bilirubin levels checked before discharge.

Diagnosis

Diagnosis involves a combination of clinical assessment, laboratory testing, and, in some cases, imaging.

1. Clinical Evaluation

• Physical exam focusing on the extent of jaundice (head, trunk, extremities).
• Neurologic exam checking tone, reflexes, and response to stimuli.
• History of risk factors (maternal blood type, prematurity, family history).

2. Laboratory Tests

• Serum total bilirubin (TSB) – measured in mg/dL; an urgent result is needed.
• Direct (conjugated) vs. indirect (unconjugated) bilirubin – kernicterus results from indirect bilirubin > 20 mg/dL in term infants or lower thresholds in preterms.
• Complete blood count (CBC) and reticulocyte count – to assess hemolysis.
• Blood type and Coombs test – for immune‑mediated hemolysis.
• G6PD screening if hemolysis is suspected.
• Electrolytes, glucose, and infection work‑up (CBC, CRP, blood cultures) if sepsis is a concern.

3. Imaging and Ancillary Studies

• Transcranial ultrasound – may show basal ganglia echogenicity in severe cases.
• Magnetic resonance imaging (MRI) – the gold standard for detecting kernicterus‑related changes (T1‑hyperintensity in basal ganglia).
• Auditory brain‑stem response (ABR) testing – to evaluate early hearing loss.

4. Scoring Tools

Hospitals often use the Bhutani nomogram (a.k.a. the “bilirubin hour‑specific chart”) to decide when treatment is required based on the infant’s age in hours and bilirubin level.

Treatment Options

Management aims to rapidly lower serum bilirubin, prevent further neurotoxicity, and address any underlying cause.

1. Phototherapy

• First‑line treatment for most newborns with significant hyperbilirubinemia.
• Blue‑green light (425–475 nm) converts unconjugated bilirubin into water‑soluble isomers that can be excreted without conjugation.
• Intensive phototherapy (double‑surface) is used for bilirubin > 20 mg/dL or if neurologic signs appear.

2. Exchange Transfusion

• Indicated when bilirubin reaches neurotoxic levels despite maximal phototherapy, or when acute neurologic signs develop.
• Blood is removed and replaced with donor, compatible blood, rapidly reducing bilirubin.
• Risks include electrolyte imbalance, infection, and transfusion reactions; performed in a NICU by experienced staff.

3. Intravenous Immunoglobulin (IVIG)

• Useful for immune‑mediated hemolysis (e.g., Rh or ABO incompatibility) when exchange transfusion is not immediately available.
• Reduces hemolysis by blocking Fc receptors.

4. Address Underlying Causes

• Treat infections with appropriate antibiotics.
• Administer glucose in hypoglycemic infants to improve bilirubin conjugation.
• For G6PD deficiency, avoid oxidative drugs and provide supportive care.
• In Crigler‑Najjar type I, liver transplantation is the definitive cure; meanwhile, aggressive phototherapy and potential experimental therapies (gene therapy) are used.

5. Supportive & Home Care

• Frequent feeding (every 2–3 hours) to promote stool output and bilirubin excretion.
• Monitor weight and hydration status.
• Educate parents on signs of worsening jaundice.

Prevention Tips

Most cases of kernicterus are preventable with early detection and proper management of neonatal jaundice.

• Early newborn discharge screening – obtain a bilirubin level before discharge, especially for at‑risk infants.
• Follow‑up visits – schedule a pediatric check‑up within 48 hours of birth for term babies, sooner for preterms.
• Encourage frequent, effective breastfeeding – aim for 8–12 feeds per day to prevent dehydration.
• Identify high‑risk mothers – those with blood‑type incompatibility, prior infant with severe jaundice, or known G6PD deficiency.
• Use transcutaneous bilirubin meters when available for rapid, non‑invasive screening.
• Educate caregivers about the normal timeline of physiologic jaundice and when to call the doctor.
• Avoid medications that displace bilirubin (e.g., certain sulfonamides) in breastfeeding mothers unless essential.
• Consider prophylactic phototherapy for very low‑birth‑weight infants (< 1500 g) or those with known hemolytic disease.

Emergency Warning Signs

Key Takeaways

• Kernicterus results from extremely high levels of unconjugated bilirubin crossing into the brain.
• Common causes include hemolytic disease, G6PD deficiency, prematurity, and severe physiologic jaundice.
• Neurologic signs may appear as lethargy, seizures, abnormal movements, hearing loss, or developmental delay.
• Early detection, prompt phototherapy, and, when needed, exchange transfusion are lifesaving.
• Most cases are preventable through routine newborn bilirubin screening and vigilant follow‑up.

For up‑to‑date guidelines, consult reputable sources such as the Mayo Clinic, CDC, NIH, and the World Health Organization. If you suspect your infant may be developing kernicterus, seek medical care immediately—early intervention can prevent permanent brain injury.

```